Drug intelligence / Profile preview

TEI-W00595

Development stage: Unknown
Lead developer: Teijin
Modality: Small Molecules
Administration: Oral

Overview

TEI-W00595 is a metabolite of TCK-276, an investigational orally administered small molecule developed for the treatment of rheumatoid arthritis. TCK-276 undergoes metabolic conversion in the body to produce TEI-W00595, which is analyzed in clinical studies for its pharmacokinetic properties including plasma concentration, distribution, elimination half-life, and metabolic ratio. TEI-W00595 is not administered directly but is formed following oral dosing of TCK-276. The precise mechanism of action for TEI-W00595 is not detailed in public sources, but it is studied as part of the pharmacokinetic and safety evaluation of TCK-276 in rheumatoid arthritis patients[3].

Other names: TEI-W00595TEI-W-00595TEI-W 00595

Beyond the preview

Go deeper on TEI-W00595.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TEI-W00595.

Explore the full profile